Martina Weise

Kurt Georg Kiesinger Allee 3
Bonn, NW 53175, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

The Tailored Biosimilar Approach: Expectations and Requirements.

The Tailored Biosimilar Approach: Expectations and Requirements.

Journal: Drugs

Published: February 24, 2025

Tofersen for SOD-1-associated amyotrophic lateral sclerosis.

Tofersen for SOD-1-associated amyotrophic lateral sclerosis.

Journal: The Lancet. Neurology

Published: May 22, 2024

Rapid differentiation of MOGAD and MS after a single optic neuritis.

Rapid differentiation of MOGAD and MS after a single optic neuritis.

Journal: Journal of neurology

Published: May 22, 2024

Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?

Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 27, 2023

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.

Journal: Scientific reports

Published: May 11, 2023

A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.

A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.

Journal: Clinical pharmacology and therapeutics

Published: August 31, 2022

Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience.

Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: April 13, 2022

WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June - 2 July 2021.

WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June - 2 July 2021.

Journal: Biologicals : journal of the International Association of Biological Standardization

Published: January 07, 2022

The EU Response to the Presence of Nitrosamine Impurities in Medicines.

The EU Response to the Presence of Nitrosamine Impurities in Medicines.

Journal: Frontiers in medicine

Published: September 24, 2021

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.

Journal: Clinical pharmacology and therapeutics

Published: April 23, 2021

Biosimilars in the European Union: current situation and challenges

Biosimilars in the European Union: current situation and challenges

Journal: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Published: May 19, 2020

Evolution of the EU Biosimilar Framework: Past and Future.

Evolution of the EU Biosimilar Framework: Past and Future.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 22, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026